LINK PHARMA CHEM Q2 : STANDALONE NET PROFIT TURNAROUND TO LOSS AT ₹0.22 CR (YOY), PROFIT VS LOSS (QOQ). WEAK (On 1st Look)

Revenue down 15.3% at ₹5.33 Cr (YOY), down 39.2% (QOQ). PBT loss at ₹0.26 Cr v profit ₹0.02 Cr (YOY); total expenses ₹5.54 Cr v ₹6.33 Cr (YOY). Finance costs ₹1.71 L; depreciation ₹28.13 L; employee benefits ₹1.48 Cr v ₹1.59 Cr (QOQ). H1 revenue flat at ₹14.10 Cr (YOY); H1 PAT down 77.2% at ₹0.10 Cr. Caution: other income negative ₹5.48 L in Q2 on ₹5.79 L FVTPL fair value loss.

Link Pharma Chem Ltd

Open attachment

← Back to feed